Basic Information
Gencebok
Regulatory Information
EMEA/H/C/005435
Authorised
August 19, 2020
June 25, 2020
8
March 12, 2025
Company Information
13127 vitrolles - france
Swen Parc de Vitrolles Chemin de la Bastide Blanche
GENNISIUM PHARMA
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of primary apnoea of premature newborns.
Overview Summary
Gencebok is a stimulant medicine used for treating apnoea of prematurity, a condition in which babies born prematurely stop breathing for longer than 20 seconds. Gencebok contains the active substance caffeine citrate. Gencebok is a ‘hybrid’ medicine. This means that it is similar to a ‘reference medicine’ containing the same active substance, but at a different strength. The reference medicine for Gencebok is Peyona.